Schrödinger (SDGR) Q1 2026 earnings review
Trust the Metric, Ignore the GAAP: The SaaS Transition Takes Hold
Schrödinger is asking investors to look past a highly distorted income statement this quarter. The company’s planned transition to hosted (SaaS) software contracts triggered a massive 21% YoY drop in recognized software revenue. However, the underlying business is showing resilience: Annual Contract Value (ACV)—management's preferred metric—grew 12% to $28.4M. Meanwhile, Drug Discovery revenue spiked 124%, though this was partially artificially inflated by the accelerated recognition of a discontinued program. The $2.3B acquisition of co-founded Ajax Therapeutics by Lilly provides crucial external validation for Schrödinger's 'physics-first' platform, but execution risk remains elevated as the company navigates this revenue model transition while launching its new agentic AI, Bunsen.
🐂 Bull Case
Lilly's $2.3B acquisition of Ajax Therapeutics (co-founded by Schrödinger, ~6% equity stake) proves the terminal value of the computational platform. Molecules designed here are commanding massive premiums in the open market.
Despite the optical revenue miss, Q1 ACV grew 12% YoY to $28.4M, and FY26 guidance targets 10-15% growth. The underlying demand for the software remains intact as the delivery model shifts.
🐻 Bear Case
Software gross margins dropped to 69% from 72% a year ago (and are far below historical levels of ~80%). The transition to cloud hosting is dragging heavily on unit economics.
Drug Discovery revenue jumped to $22.9M, but this was heavily aided by deferred revenue recognition from a discontinued program, setting up a difficult comparative hurdle for future quarters.
⚖️ Verdict: ⚪
Neutral. The optical top-line decline was fully telegraphed, and ACV growth is solid. However, the combination of margin compression and reliance on one-time accounting boosts in Drug Discovery keeps us cautious until the hosted transition matures.
Key Themes
Agentic AI Launch: Introducing 'Bunsen'
Schrödinger is launching 'Bunsen' this summer. This is an agentic AI co-scientist designed to autonomously execute complex molecular discovery workflows. This represents a major product evolution from human-driven software to autonomous task execution, potentially expanding the user base beyond highly specialized computational chemists and driving heavier platform utilization.
Strategic Therapeutics Partnering
The company's pivot toward a discovery-stage R&D model (ceasing independent clinical development) is bearing fruit. The $2.3B Ajax acquisition by Lilly highlights the latent value in the portfolio. Management is currently actively seeking strategic partners for mid-and late-stage development of its internal assets, SGR-1505 and SGR-3515.
Gross Margin Deterioration Contradicts SaaS Narrative
Management champions the shift to a hosted SaaS model as a positive evolution, but the data tells a painful near-term story. Software gross margin compressed to 69% in 26Q1, down from 72% in 25Q1 and significantly below the ~80% historical norm. The costs of cloud hosting are compressing unit economics precisely when top-line growth is already optically suppressed.
Low-Quality Earnings Boost in Drug Discovery
Drug Discovery revenue surged 124% YoY to $22.9M. However, management noted this was driven by 'the discontinuation of one collaboration program,' triggering accelerated recognition of deferred revenue. This is a one-time, low-quality revenue event that masks the true underlying growth run-rate of the collaboration portfolio.
Biopharma Macro Environment Stabilizing
After multiple quarters of citing 'severe headwinds' and 'budget constraints' in the biotech sector, CEO Ramy Farid explicitly noted that 'the biopharmaceutical funding environment is improving.' If true, this removes a major overhang that capped new logo acquisition throughout 2025.
Other KPIs
Reversing. Down 21% YoY from $45.0 million. This is the anticipated mathematical consequence of accelerating the shift from upfront on-premise licensing to ratable hosted software deployment. Investors must decouple this reported GAAP number from actual commercial momentum.
Stable. Down 4% YoY from $82.0 million. Management is successfully executing the $70M annualized cost-saving initiatives (announced in mid-2025), driven by reduced R&D (-4.4% YoY) and G&A (-11.2% YoY) as the company ceases independent clinical trials.
Decelerating slightly. The company burned $14.8M in operating cash flow this quarter, a reversal from the $144M generated in 25Q1 (which included a massive upfront payment from Novartis). However, with over $400M on the balance sheet and falling OpEx, capitalization remains strong.
Guidance
Accelerating. The midpoint of $223M implies ~12.3% YoY growth, a significant acceleration compared to the sluggish 4% ACV growth printed in FY25. This is the critical metric proving the software business is still expanding.
Stable. Midpoint implies roughly 6% growth over FY25's $56.4M. Given that Q1 already printed $22.9M (aided by a discontinued program), the implied run-rate for the remaining three quarters is a relatively weak ~$12M per quarter.
Decelerating sequentially. Down from Q1's $28.4M, reflecting typical enterprise software seasonality where Q1 sees strong scale-ups and Q4 handles the bulk of renewals.
Key Questions
Drug Discovery Run-Rate
Exactly how much of the $22.9M in Q1 Drug Discovery revenue was tied to the discontinued program, and what does the normalized quarterly baseline look like for the rest of FY26?
Hosted Margin Floor
Software gross margins dropped to 69% this quarter. At what point in the transition to 75% hosted revenue (targeted for 2028) do you expect gross margins to bottom out, and what is that floor?
Bunsen Monetization Strategy
Will the new agentic AI 'Bunsen' be monetized as a separately priced add-on module, or is it included in the core platform to drive higher throughput utilization and scale-up ACV?